Clootrack analyzed 95,854 consumer conversations to map how GLP-1 adoption is restructuring demand across grocery, apparel, beauty, and fitness before it shows up in transaction data.
New York, NY, United States – April 02, 2026: GLP-1 medications used to be a healthcare story. In 2026, they are a retail planning problem.
J.P. Morgan projects approximately 25 million Americans on GLP-1 treatment by 2030, up from around 10 million in 2025. Oral formulations launching this year will push that number higher.
To map how that growth is changing retail behavior, Clootrack analyzed 95,854 GLP-1 consumer conversations collected between January 2022 and December 2025, extracting 340,725 opinions using its Voice of Customer analytics platform.
Clootrack was recognized by OpenAI last year for processing over 100 billion tokens in Voice of the Customer analytics.
What emerged was not demand contraction. It was demand reorganization. Consumer behavior is being restructured in ways that purchase data alone cannot reveal.
Retailers plan promotions on monthly calendars. GLP-1 users live on weekly pharmaceutical cycles.
The injection cycle creates a predictable demand pulse inside every single week. Days 1 to 3 bring appetite suppression and nausea sensitivity. Days 4 to 5 stabilize. Days 6 to 7 bring appetite return and food re-engagement.
“The first 3 days after my dose, I’m buying ginger ale, crackers, and soup. The last 3 days, I’m buying real groceries. My cart looks completely different depending on where I am in my week.”
The commercial consequence is direct. Stock-up promotions and fresh food deals timed to early-week cycles miss the purchase window entirely. Standard forecasting models are not built to detect this.
Traffic is rising in apparel. Conversion is not following.
Across 6,464 body image-related mentions, positive sentiment is only 48.5%, a divided psychological state rather than the empowerment retailers expect from weight-loss customers.
Consumers describe feeling lighter but not smaller, seeing physical change but not trusting its permanence, and hesitating to invest in wardrobes before weight loss stabilizes.
“I went shopping three times last month and bought nothing. I don’t know what size I am. I don’t know what fits. I just stood there and left.”
Body Satisfaction registers high volume and above-average positivity, while Body Dysmorphia and Social Perception cluster in the low-positivity zone, reflecting a consumer base that is physically lighter but psychologically divided.
The risk: discounting into softening conversion is the wrong response. Price cuts do not solve psychological lag. Retailers who misdiagnose hesitation as demand decline may erode margin without unlocking a single additional conversion.
The fastest-growing theme in the appearance dataset is cosmetic interventions, surging at 927.8% month-over-month. The driver is not aspiration. It is deflation anxiety.
Weight loss changes facial volume alongside body composition. Across conversations referencing Ozempic face, only 15% express positive sentiment while mentions grow at 140.3% month-over-month.
Consumers describe hollowing under the eyes, loss of cheek fullness, increased skin laxity, and looking older despite weight loss.
“I lost 80 pounds and I look… older? My face is hollow. My neck has this weird jowl thing. My clothes hang on me but not in a good way-my arms look like bat wings in sleeveless tops.”
Appearance positivity fell from above 85% in early 2022 to approximately 43% by 2024, while all other dimensions held flat. A partial recovery to 51% by the end of 2025 reflects adaptation, not resolution.
The consumer response is a coordinated repair routine: collagen, firming serums, red light devices, assembled across aisles that retail does not merchandise as systems. The new motivation is structural skin repair, not decoration.
Retailers who continue to merchandise beauty as aspiration are speaking to a different consumer than the one now standing in their aisle.
The dominant movement signal in the dataset is not gym ambition. It is restored access.
Walking emerges as the most referenced activity, not because GLP-1 users are unambitious, but because it requires no performance threshold, no recovery window, and no gym. Mobility restoration shows 95.7% positive sentiment with 120.4% month-over-month growth.
One signal cuts against the positive momentum. Consumers are increasingly anxious about muscle loss during rapid weight reduction. Growth is high. Sentiment is negative. That combination means demand is forming from anxiety, not ambition.
“I was so focused on just getting some weight off me that I said I’ll just go walking in the beginning… And now just over 35 lb down I’m regretting that. I wish I would have done at least 10 minutes of body weight exercises or wearing a weighted vest.”
Entry-level walking gear, supportive footwear, protein positioned for retention, and wearables used as validation tools are the actual growth clusters. This is a preservation economy, not a performance boom.
The four rhythms above are each individually significant. But the dataset contains a fifth domain that cuts across all of them: a cross-category spending reorganization that reveals where the money is actually going, which categories are being funded first, and what the sequence of demand recovery looks like as GLP-1 adoption matures.
The full analysis, including all five domains and role-specific planning implications, is available in Clootrack’s 2026 retail intelligence report: The GLP-1 Effect on U.S. Retail: What Voice of Customer Data Reveals in 2026.
GLP-1 adoption is still scaling. The behavioral systems documented in this analysis are forming. Consumer routines have not yet hardened. The window to act on formation signals before they confirm in revenue is open now. It will not stay open indefinitely.
Sales data tells you what happened. Voice of Customer data tells you what is forming. In 2026, that gap is where retail performance will be decided.
Clootrack’s findings are based on the analysis of 95,854 GLP-1-related consumer conversations collected between January 2022 and December 2025 across forums, social media, and health review sites. The platform extracted 340,725 opinions using patented unsupervised AI thematic detection, operating at 98% analysis accuracy on validated language benchmarks. All findings are directional signals derived from consumer conversation data and do not represent verified sales, revenue, or market share figures. Only U.S.-based conversations were included.
VoC Research | Clootrack
contactus@clootrack.com
Author Richard Ettinger blends action, humor, and intrigue in a fast paced novel filled with…
CHARLESTON, S.C. – Today, Competitive Markets Action, Inc. (CMA), a 501(c)(4) non-profit based in Washington, D.C., with…
Anthony P. Jones delivers a fast-paced, cinematic novel set within the Catholic Church, where belief…
Animation industry leader joins as company expands its production analytics platform with the launch of…
Coworks spoke with operators and industry experts to surface the hiring practices, common pitfalls, and…
Global leaders share insights on accelerating AI-powered operational excellence. Houston, TX – Radix, a global…
This website uses cookies.